Cargo-influences on the biodistribution of hollow mesoporous silica nanoparticles as studied by quantitative19F-magnetic resonance imaging.
OBJECTIVE
Biodistribution is a key issue when it comes to medical applications of nanomaterials. Hollow mesoporous silica nanoparticles (HMSNs) loaded with fluorine compounds can be applied as positive magnetic resonance imaging (MRI) contrast agents (CAs). These CAs exhibit an unusual biodistribution which is influenced by the cargo and which could be linked to their serum protein adsorption behaviour.


METHODS
HMSNs were post-synthetically loaded with perfluoro-15-crown-5-ether (PFCE). The19F signal was quantified with MRI in a murine model. Furthermore protein adsorption tests were performed in full serum.


RESULTS
Quantitative analysis of the19F-signal revealed that the particles were exclusively accumulating in the liver 24h post-injection, and no accumulation in other reticuloendothelial system (RES) organs like spleen or lung was observed. The protein corona around non-loaded and loaded particles was therefore analysed, and more proteins adsorbed on PFCE-loaded particles as compared to the bare particles, and importantly, the amount of apolipoproteins A-1 and A-2, was clearly elevated for the PFCE-loaded particles. The results underline that the type of cargo may have major influences on the biodistribution of mesoporous silica drug vectors.
Inorganic Chemistry II, Ulm University, Albert-Einstein-Allee 11, 89081 Ulm, Germany.
Alexander
A
Pochert
Core Facility Small Animal MRI, Ulm University, Albert-Einstein-Allee 23, 89081 Ulm, Germany.
Ina
I
Vernikouskaya
Inorganic Chemistry II, Ulm University, Albert-Einstein-Allee 11, 89081 Ulm, Germany.
Felix
F
Pascher
Core Facility Small Animal MRI, Ulm University, Albert-Einstein-Allee 23, 89081 Ulm, Germany. Electronic address: volker.rasche@uniklinik-ulm.de.
Volker
V
Rasche
Inorganic Chemistry II, Ulm University, Albert-Einstein-Allee 11, 89081 Ulm, Germany. Electronic address: mika.linden@uni-ulm.de.
Mika
M
Lindén
D000327:Adsorption; D000818:Animals; D016632:Apolipoprotein A-I / Q000097:blood* / Q000737:chemistry; D016633:Apolipoprotein A-II / Q000097:blood* / Q000737:chemistry; D003287:Contrast Media / Q000737:chemistry* / Q000493:pharmacokinetics; D043844:Crown Ethers / Q000737:chemistry* / Q000493:pharmacokinetics; D004339:Drug Compounding; D005461:Fluorine / Q000737:chemistry / Q000493:pharmacokinetics; D066235:Fluorine-19 Magnetic Resonance Imaging; D008099:Liver / Q000000981:diagnostic imaging* / Q000378:metabolism; D051379:Mice; D053758:Nanoparticles / Q000737:chemistry* / Q000648:ultrastructure; D016062:Porosity; D012822:Silicon Dioxide / Q000737:chemistry* / Q000493:pharmacokinetics; D014018:Tissue Distribution; D005466:Fluorocarbons
D016632:Apolipoprotein A-I; D016633:Apolipoprotein A-II; D003287:Contrast Media; D043844:Crown Ethers; D005461:Fluorine; D012822:Silicon Dioxide; C089317:perfluoro-15-crown-5-ether; D005466:Fluorocarbons
(19)F MRI; 2D PAGE; Biodistribution; Contrast agent; HMSNs; In vivo; Mesoporous silica nanoparticles; PFCE; Protein adsorption; Quantification